This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mesa Labs Reports Quarterly Sales And Earnings

For the quarter, DataTrace sales decreased 10 percent compared to the same period last year, while sales decreased 16 percent for the nine month period compared to the same period last year.  This business is recovering as the capital spending environment improves.  DataTrace sales during the most recent 6 months (Q2 and Q3 of this fiscal year) increased 16% compared to the previous 6 month period (Q4 of FY'09 and Q1 of FY'10), which was during the worst part of the recession in terms of capital spending.  Although this product line is not back to pre-recession levels, the trend is encouraging.  For the quarter and first nine month periods, sales of the newer Micropack RF products have increased significantly, indicating a shift away from the older Micropack III loggers to the newer technology.

During the third quarter and first nine months of fiscal 2010 sales of Raven biological indicator products increased four percent and eight percent, respectively, compared to the prior year period.  The increase in Raven sales for both the quarter and nine month periods was due to increases in sales of the biological indicator and chemical indicator products, which were partially offset by decreases in accessories and contract consulting.

Profitability for the third quarter and nine month periods of fiscal 2010 was down compared to the prior fiscal year due to the small decrease in revenues and a shift in overall product mix between the instrument and Biological Indicator product lines.  The shift in product mix, along with a more competitive pricing environment for the DataTrace products suppressed gross margins, which was not fully offset by reduced operating expenses.  For the quarter and first nine month periods, net income decreased five percent during each period, when compared to the prior year.  

During the first nine months of fiscal 2010, the Company repurchased 11,328 shares of our common stock under a previously announced buyback plan for approximately $263,000.  In addition, the Company had a remaining commitment of approximately $158,000 for Vibrac inventory, which was paid in January, 2010, and $100,000 for holdbacks to be paid to Vibrac LLC, which is due in December, 2010.

Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
MLAB $83.83 0.00%
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%
TSLA $226.03 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs